BimEL-I146Y-Q148R

General Information


DRACP ID  DRACP03039

Peptide Name   BimEL-I146Y-Q148R

Sequence  LRPEIRYARELRRIGDEFNE

Sequence Length  20

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Cancer targeted peptides Induce apoptosis Bcl-xL/Bac-2 inhibitors BH3 peptides and mimetics



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Bcl-2/Bcl-xL

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP03039

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C110H178N36O33

Absent amino acids  CHKMQSTVW

Common amino acids  R

Mass  287191

Pl  6.69

Basic residues  5

Acidic residues  5

Hydrophobic residues  6

Net charge  0

Boman Index  -9193

Hydrophobicity  -128

Aliphatic Index  83

Half Life 
  Mammalian: 5.5 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  1490

Absorbance 280nm  78.42

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 30860026

Title  Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2

Doi 10.7554/eLife.37689

Year  2019

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.